spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Jerini 

 HSMN NewsFeed - 10 Sep 2019
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 28 Feb 2011
Shire Files Complete Response to FDA's Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 4 Nov 2008
SurModics Acquires Drug Delivery Assets of PR Pharmaceuticals
Biopharmaceuticals Drug Delivery Acquisitions
 HSMN NewsFeed - 7 Oct 2008
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 15 Jul 2008
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jul 2008
Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Apr 2008
Jerini Receives Positive CHMP Opinion Recommending European Approval for Icatibant in the Treatment of HAE; FDA Issues Not Approvable Letter
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Apr 2008
Jerini AG -- FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAE
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Oct 2007
Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Sep 2007
Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2006
Kos Announces Positive Overall Results for Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2006
Baxter and Jerini Advance Program to Develop Non-Intravenous Hemophilia Therapy
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
Jerini
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.